October 1, 2019
Astellas/Seattle Genetics’ investigational antibody drug conjugate (ADC) enfortumab vedotin in combination with the anti-PD-1 antibody Keytruda (pembrolizumab) has demonstrated an objective response rate (ORR) of 71% in a PI study in 45 previously untreated patients with locally advanced or metastatic...read more